



## **JMCC Appoints Dr. Evan Cole Lewis as Chief Medical Advisor**

*Director of renowned Neurology Centre of Toronto an innovator in cannabis-based treatments for epilepsy and other neurological conditions.*

Toronto, June 18, 2020/ Diane Scott, Group Chair & CEO of Toronto-headquartered JMCC announced today that Dr. Evan Cole Lewis, MD, FRCPC, CSCN EEG Diplomate, has been appointed as the company's Chief Medical Advisor.

As Director of the Neurology Centre of Toronto (NCT), Dr. Lewis leads a team of skilled neurologists, neurology-related specialists and allied health practitioners committed to delivering comprehensive and timely neurologic care that is organized around the needs of patients and their families to address the complex conditions that affect patients' health and well-being. He established NCT in January 2017.

Dr. Lewis is a Pediatric Neurologist and Clinical Neurophysiologist with expertise in epilepsy, epilepsy surgery, electroencephalography (EEG), virtual medicine and medical cannabis for the treatment of neurologic disorders. At NCT, Dr. Lewis treats children with a variety of neurological disorders and he also treats adults for concussion, headache and epilepsy.

Dr. Lewis' interest in medical cannabis began in 2013 while training at Nicklaus Children's Hospital (formerly Miami Children's Hospital). He has since developed significant clinical experience with medical cannabis in adults and children. He is a member of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), the Canadian Childhood Cannabinoid Clinical Trials (C4T), and the Cannabinoid Research Initiative of Saskatchewan (CRIS). He is a contributor and principal applicant on two major pending Canadian grants in clinical cannabis research.

Dr. Lewis attained his MD from the University of Ottawa and trained as a Pediatric Neurologist at the Children's Hospital of Eastern Ontario (CHEO). He completed

fellowships in both clinical neurophysiology and epilepsy at Nicklaus Children's Hospital and the Hospital for Sick Children in Toronto. Dr. Lewis was a staff neurologist, clinical neurophysiologist and the Director of the Epilepsy Fellowship Training Program at the Hospital for Sick Children between 2015 and 2016. He also held a staff position as the primary neurologist for the Early Care Concussion Clinic at Holland Bloorview Kids Rehabilitation Hospital from 2016 – 2018.

Dr. Lewis is an Adjunct Assistant Professor at the University of Toronto, a Fellow of the Royal College of Physicians of Canada and was the Tariff Chair of the Neurology Section for the Ontario Medical Association from 2017 – 2019. He is an ad-hoc reviewer for the *Canadian Journal of Neurological Sciences* and *Paediatrics & Child Health*. His research and special interests include cannabinoids in the treatment of epilepsy and other neurological conditions, concussion, epilepsy, headache and improving patient access through the use of virtual medicine.

In his role as Chief Medical Advisor, Dr. Lewis will guide the research and development of cannabis-based treatments for epilepsy and other conditions at JMCC's Scientific division, working with specialist advisors in other fields.

"We are so pleased that a medical innovator of Evan's calibre has agreed to serve as JMCC's Chief Medical Advisor," Diane Scott said. "After meeting him a year ago, when he agreed to speak at our Medical Cannabis Symposium held in London (UK), I've only become more impressed by his dedication to advancing research in areas including medical cannabis and his personal mission to offer the best treatment options for patients."

"I'm looking forward to working closely with Diane and the JMCC Scientific team," Dr. Lewis said. "I've been intrigued by the company's commitment to evidence-based research to develop safe and effective treatments with cannabis, and its leadership in supporting ground-breaking initiatives like Project Twenty21 in the UK. I'm delighted to have the opportunity to help build and work with a world-class team of medical advisors all committed to the same goals."

Dr. Lewis' appointment as JMCC's Chief Medical Advisor is effective today.

--END--

For more information, contact:

Shelley Boyes

Global Marketing & Communications Director, JMCC

T: +1 416.272.8981

E: [shelley.boyes@jamaicanmedicann.com](mailto:shelley.boyes@jamaicanmedicann.com)

Andrea Chrysanthou

Global Public Affairs

T: +1 416.797-8194

E: [achrysanthou@globalpublic.com](mailto:achrysanthou@globalpublic.com)

### **About JMCC**

Founded in 2016, JMCC Group is the leading provider of high-quality Jamaican medical cannabis products and services to the world. Headquartered in Toronto, Canada, the company serves customers in Australia, Canada, the EU and UK, and Latin America.

JMCC combines Jamaica's natural, year-round growing climate and distinctive cannabis landraces with an unswerving commitment to meeting or exceeding international standards for quality, safety, security and sustainability.

JMCC Scientific encompasses medical product R&D, testing, manufacturing, packaging and labelling, and distribution to our customers globally via our state-of-the-art warehousing and logistics systems.

Learn more at <https://www.jamaicanmedicann.com/>.